GGrantIndex
← Leaderboards

Heidi M. Crane

University Of Washington

Google Scholar ↗PubMed ↗ORCID ↗
$25,961,202
Attributed
$56,381,869
Total exposure
24
Grants
17
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $5.3M · FY2005–25
$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$54,772,013 · 22
AHRQ$1,609,856 · 2

By mechanism

R01$26,152,371 · 8
U01$15,067,203 · 3
U24$6,424,229 · 2
R33$3,979,822 · 1
U18$1,193,479 · 1
R56$1,159,176 · 2

Top collaborators

Most similar at University Of Washington

Same institution · by research overlap

Others in their field

Top investigators on “Caring”

Research focus

CaringCohortResourcesSiteClinical DataAntiretroviral TherapyClinical CareAcquired Immunodeficiency SyndromePharmaceutical PreparationsPersonsComorbidityRisk FactorsResponsePatient Outcomes AssessmentsResearch PersonnelAdjudicationPatternAgingMortalityInterestHiv InfectionsInfrastructureLinkClinical Research Site

Grant awards (91)

HIV and Substance Use Cohort Coordinating Center for Emerging and High Impact Scientific Cross Cohort Studies: HIV SUCCESS$929,341
U24 · FY2025 · DA · contact PI
AIDS and Aging Research Platform (AARP)$753,490
R33 · FY2025 · AG · contact PI
Clonal hematopoiesis, epigenetic changes, social determinants of health, and behavioral risk factors as predictors of accelerated aging in HIV$703,644
R01 · FY2025 · AG
Comorbidities and other consequences at the intersection of the HIV and substance use epidemics$688,290
R01 · FY2025 · DA · contact PI
Links between Cardiovascular disease, Lung disease, and Obstructive sleep apnea in HIV: Understanding complex patients$667,628
R01 · FY2025 · HL · contact PI
Alcohol Research Consortium in HIV: Epidemiology Research Arm$183,015
P01 · FY2025 · AA · contact PI
HIV and Substance Use Cohort Coordinating Center for Emerging and High Impact Scientific Cross Cohort Studies: HIV SUCCESS$838,133
U24 · FY2024 · DA · contact PI
Understanding Health Inequities at the Intersection of the HIV and substance use epidemics across racial/ethnic and other underserved populations$683,757
R01 · FY2024 · DA · contact PI
Links between Cardiovascular disease, Lung disease, and Obstructive sleep apnea in HIV: Understanding complex patients$675,830
R01 · FY2024 · HL · contact PI
Alcohol Research Consortium in HIV: Epidemiology Research Arm$182,198
P01 · FY2024 · AA · contact PI
HIV and Substance Use Cohort Coordinating Center for Emerging and High Impact Scientific Cross Cohort Studies: HIV SUCCESS$939,038
U24 · FY2023 · DA · contact PI
Pharmacogenomics and Systems Pharmacology Approaches to Toxicity, Tolerability, and Comorbidities Associated with Modern Antiretroviral Therapies$823,490
R01 · FY2023 · HG
AIDS and Aging Research Platform (AARP)$769,862
R33 · FY2023 · AG · contact PI
Understanding Health Inequities at the Intersection of the HIV and substance use epidemics across racial/ethnic and other underserved populations$738,902
R01 · FY2023 · DA · contact PI
Rural Comorbidity and HIV consequences of Opioid use Research and Treatment Initiative (Rural cohort)$733,846
U24 · FY2023 · DA · contact PI
Links between Cardiovascular disease, Lung disease, and Obstructive sleep apnea in HIV: Understanding complex patients$685,518
R01 · FY2023 · HL · contact PI
Genetic Predisposition and Pharmacogenomics of HIV-Associated Cognitive Impairment$400,773
R01 · FY2023 · HG
Alcohol Research Consortium in HIV: Epidemiology Research Arm$181,698
P01 · FY2023 · AA · contact PI
Pharmacogenomics and Systems Pharmacology Approaches to Toxicity, Tolerability, and Comorbidities Associated with Modern Antiretroviral Therapies$823,609
R01 · FY2022 · HG
Genes, substance use, and HIV outcomes in people living with HIV across the US$780,507
R01 · FY2022 · DA · contact PI
AIDS and Aging Research Platform (AARP)$770,820
R33 · FY2022 · AG · contact PI
Rural Comorbidity and HIV consequences of Opioid use Research and Treatment Initiative (Rural cohort)$739,908
U24 · FY2022 · DA · contact PI
Links between Cardiovascular disease, Lung disease, and Obstructive sleep apnea in HIV: Understanding complex patients$739,732
R01 · FY2022 · HL · contact PI
Effectiveness of a smoking cessation algorithm integrated into HIV primary care$721,940
R01 · FY2022 · DA
Alcohol Research Consortium in HIV: Epidemiology Research Arm$181,992
P01 · FY2022 · AA · contact PI
Genes, substance use, and HIV outcomes in people living with HIV across the US$1,042,014
R01 · FY2021 · DA · contact PI
Pharmacogenomics and Systems Pharmacology Approaches to Toxicity, Tolerability, and Comorbidities Associated with Modern Antiretroviral Therapies$827,529
R01 · FY2021 · HG
AIDS and Aging Research Platform (AARP)$774,628
R33 · FY2021 · AG · contact PI
Rural Comorbidity and HIV consequences of Opioid use Research and Treatment Initiative (Rural cohort)$754,049
U24 · FY2021 · DA · contact PI
Effectiveness of a smoking cessation algorithm integrated into HIV primary care$658,700
R01 · FY2021 · DA
Implementation and Evaluation of psPRO: Person-specific Patient-Reported Outcome Assessments for Patients in HIV Care living with Multiple Chronic Conditions$398,046
U18 · FY2021 · HS · contact PI
Alcohol Research Consortium in HIV: Epidemiology Research Arm$185,680
P01 · FY2021 · AA · contact PI
Genes, substance use, and HIV outcomes in people living with HIV across the US$159,270
R01 · FY2021 · DA · contact PI
AIDS and Aging Research Platform (AARP)$100,047
R33 · FY2021 · AG · contact PI
Pharmacogenomics and Systems Pharmacology Approaches to Toxicity, Tolerability, and Comorbidities Associated with Modern Antiretroviral Therapies$824,847
R01 · FY2020 · HG
AIDS and Aging Research Platform (AARP)$810,975
R33 · FY2020 · AG · contact PI
Genes, substance use, and HIV outcomes in people living with HIV across the US$790,896
R01 · FY2020 · DA · contact PI
Rural Comorbidity and HIV consequences of Opioid use Research and Treatment Initiative (Rural cohort)$754,049
U24 · FY2020 · DA · contact PI
3/4 Alcohol Research Consortium in HIV - Epidemiological Research Arm (ARCH-ERA)$669,602
U01 · FY2020 · AA · contact PI
Effectiveness of a smoking cessation algorithm integrated into HIV primary care$661,921
R01 · FY2020 · DA
Implementation and Evaluation of psPRO: Person-specific Patient-Reported Outcome Assessments for Patients in HIV Care living with Multiple Chronic Conditions$397,964
U18 · FY2020 · HS · contact PI
Marijuana policy change impact on patterns of marijuana and other harmful substance use among people living with HIV: A mixed methods evaluation$194,375
R21 · FY2020 · DA
Effectiveness of a smoking cessation algorithm integrated into HIV primary care$97,064
R01 · FY2020 · DA
Pharmacogenomics and Systems Pharmacology Approaches to Toxicity, Tolerability, and Comorbidities Associated with Modern Antiretroviral Therapies$839,731
R01 · FY2019 · HG
Genes, substance use, and HIV outcomes in people living with HIV across the US$790,896
R01 · FY2019 · DA · contact PI
Rural Comorbidity and HIV consequences of Opioid use Research and Treatment Initiative (Rural cohort)$735,865
U24 · FY2019 · DA · contact PI
3/4 Alcohol Research Consortium in HIV - Epidemiological Research Arm (ARCH-ERA)$680,962
U01 · FY2019 · AA · contact PI
Effectiveness of a smoking cessation algorithm integrated into HIV primary care$661,628
R01 · FY2019 · DA
Implementation and Evaluation of psPRO: Person-specific Patient-Reported Outcome Assessments for Patients in HIV Care living with Multiple Chronic Conditions$397,469
U18 · FY2019 · HS · contact PI
Marijuana policy change impact on patterns of marijuana and other harmful substance use among people living with HIV: A mixed methods evaluation$233,250
R21 · FY2019 · DA
Seek, Test, Treat, and Retain Data Harmonization Coordinating Center$153,227
U01 · FY2019 · DA
Genes, substance use, and HIV outcomes in people living with HIV across the US$830,691
R01 · FY2018 · DA · contact PI
Effectiveness of a smoking cessation algorithm integrated into HIV primary care$741,283
R01 · FY2018 · DA
3/4 Alcohol Research Consortium in HIV - Epidemiological Research Arm (ARCH-ERA)$686,094
U01 · FY2018 · AA · contact PI
Seek, Test, Treat, and Retain Data Harmonization Coordinating Center$684,004
U01 · FY2018 · DA
Cardiovascular, Pulmonary & Hematological Disease in HIV: Prevention & Treatment$777,434
R01 · FY2017 · HL · contact PI
Genomic approaches to cardiometabolic risk and treatment in HIV$759,333
R01 · FY2017 · HL
3/4 Alcohol Research Consortium in HIV - Epidemiological Research Arm (ARCH-ERA)$697,668
U01 · FY2017 · AA · contact PI
Seek, Test, Treat, and Retain Data Harmonization Coordinating Center$690,557
U01 · FY2017 · DA
Epidemiology of HIV-Related Atrial Fibrillation$359,808
R56 · FY2017 · AG
Seek, Test, Treat, and Retain Data Harmonization Coordinating Center$92,688
U01 · FY2017 · DA
Cardiovascular, Pulmonary & Hematological Disease in HIV: Prevention & Treatment$763,655
R01 · FY2016 · HL · contact PI
3/4 Alcohol Research Consortium in HIV - Epidemiological Research Arm (ARCH-ERA)$740,843
U01 · FY2016 · AA · contact PI
Genomic approaches to cardiometabolic risk and treatment in HIV$714,351
R01 · FY2016 · HL
Seek, Test, Treat, and Retain Data Harmonization Coordinating Center$688,114
U01 · FY2016 · DA
Cardiovascular, Pulmonary & Hematological Disease in HIV: Prevention & Treatment$811,316
R01 · FY2015 · HL · contact PI
Genomic approaches to cardiometabolic risk and treatment in HIV$700,862
R01 · FY2015 · HL
Seek, Test, Treat, and Retain Data Harmonization Coordinating Center$700,647
U01 · FY2015 · DA
Cardiovascular, Pulmonary and Hematological Disease in HIV: Prevention and Treatment$799,368
R56 · FY2014 · HL · contact PI
Seek, Test, Treat, and Retain Data Harmonization Coordinating Center$745,365
U01 · FY2014 · DA
Genomic approaches to cardiometabolic risk and treatment in HIV$709,888
R01 · FY2014 · HL
Patient reported outcomes in routine clinical care of patients infected with HIV$426,601
U01 · FY2013 · AR · contact PI
Patient reported outcomes in routine clinical care of patients infected with HIV$1,975,638
U01 · FY2012 · AR · contact PI
Optimal assessment of HAART adherence in routine clinical care$529,285
R01 · FY2012 · MH · contact PI
Patient reported outcomes in routine clinical care of patients infected with HIV$1,487,276
U01 · FY2011 · AR
Patient reported outcomes in routine clinical care of patients infected with HIV$812,670
U01 · FY2011 · AR
Optimal assessment of HAART adherence in routine clinical care$531,130
R01 · FY2011 · MH · contact PI
Patient reported outcomes in routine clinical care of patients infected with HIV$1,534,944
U01 · FY2010 · AR
Optimal assessment of HAART adherence in routine clinical care$550,200
R01 · FY2010 · MH · contact PI
Comparative effectiveness of lipid-lowering and antihypertensive medications amon$416,377
R21 · FY2010 · HS · contact PI
Patient reported outcomes in routine clinical care of patients infected with HIV$1,600,303
U01 · FY2009 · AR
Optimal assessment of HAART adherence in routine clinical care$718,593
R01 · FY2009 · MH · contact PI
Optimal assessment of HAART adherence in routine clinical care$526,234
R01 · FY2008 · MH · contact PI
Lipodystrophy among HIV-infected patients$126,306
K23 · FY2008 · AI · contact PI
Lipodystrophy among HIV-infected patients$126,306
K23 · FY2007 · AI · contact PI
LIPODYSTROPHY AMONG EXTENSIVELY TREATED HIV-INFECTED PATIENTS$3,435
M01 · FY2007 · RR · contact PI
LIPODYSTROPHY AMONG EXTENSIVELY TREATED HIV-INFECTED PATIENTS: RENAL FUNCTION$490
M01 · FY2007 · RR · contact PI
Lipodystrophy among HIV-infected patients$126,306
K23 · FY2006 · AI · contact PI
LIPODYSTROPHY AMONG EXTENSIVELY TREATED HIV-INFECTED PATIENTS$11,549
M01 · FY2006 · RR · contact PI
Lipodystrophy among HIV-infected patients$126,306
K23 · FY2005 · AI
Lipodystrophy among HIV-infected patients$126,306
K23 · FY2004 · AI